Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05189275
Other study ID # 28497
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 10, 2022
Est. completion date December 31, 2022

Study information

Verified date September 2023
Source University of Northern Colorado
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cannabidiol (CBD), a non-psychoactive hemp derivative, is an attractive therapeutic target, and is most supported by the scientific community as an antiepileptic, anxiolytic, and antipsychotic. Additionally, CBD may cause alterations in aspects of health and fitness, fatigue, stress, calmness, quality of life, cognitive function, ability to maintain focus, sleep quantity, and sleep quality. Cannabidiol may be associated with alterations in inflammatory response in the human body, which has implications in both healthy and diseased populations. Natural killers cells (NKC) play a vital role in maintain your body's defenses and are an essential component of your immune system. In humans, NKC contain the highest concentrations of receptors associated with the endocannabinoid system and CBD. Human models have demonstrated that CBD use increases the percentage of NKC in peripheral blood. However, similar models found that CBD administration inhibits markers of NKC cytotoxic function, a beneficial cellular mechanism used to prevent malignant cell transformation and viral infection. The overarching goal of this investigation is to determine the effects of an 8-week CBD intervention on measures of fatigue, stress, calmness, quality of life, cognitive function, focus, health and fitness, and sleep quantity, and sleep quality. In addition, this study will explore a potential CBD mechanism of action with a focus on biomarkers of neural health, inflammation, liver health, kidney health, as well as NKC number and function.


Description:

BACKGROUND: Cannabidiol (CBD), a non-psychoactive hemp derivative, is an attractive therapeutic target, and is most supported by the scientific community as an antiepileptic, anxiolytic, and antipsychotic. Additionally, CBD may cause alterations in aspects of health and fitness, fatigue, stress, calmness, quality of life, cognitive function, ability to maintain focus, sleep quantity, and sleep quality. Cannabidiol may be associated with alterations in inflammatory response in the human body, which has implications in both healthy and diseased populations. In humans, natural killer cells (NKC) contain the highest concentrations of receptors associated with the endocannabinoid system and CBD. Human models have demonstrated that CBD use increases the percentage of NKC in peripheral blood. However, similar models found that CBD administration inhibits markers of NKC cytotoxic function, a beneficial cellular mechanism used to prevent malignant cell transformation and viral infection. The overarching goal of this investigation is to determine the effects of an 8-week CBD intervention on measures of fatigue, stress, calmness, quality of life, cognitive function, focus, health and fitness, and sleep quantity, and sleep quality. In addition, this study will explore a potential CBD mechanism of action with a focus on biomarkers of neural health, inflammation, liver health, kidney health, as well as NKC number and function. METHODS: In this double-blind, placebo-controlled, 4 arm clinical trial, male and female participants will undergo 2 pre intervention study visits and 3 post intervention study visits separated by an 8-week intervention period. Participants must be aged 18-50 years old, currently completing at least 150 minutes of moderate to vigorous physical activity per week, have a body mass index under 29.9, with no significant physical or mental health (without the presence of chronic depression or anxiety) conditions. Subjects may not have an allergy to soy. All study subjects must also be free of cannabis product use or regular high doses of antioxidants for the previous 8 weeks. Supplementation groups will be randomly assigned into groups consuming one of 4 beverages: 1) a beverage with 40 mg of CBD (CBD40, n=50), 2) a beverage with 20 mg of CBD (CBD20, n=50), 3) a beverage with 0 mg of CBD (CBD0, n=50) or 4) calorie-matched placebo (PLAC, n=50). INTERVENTION DESCRIPTION: Participants will be instructed to consume one beverage per day following their last meal, 1-1.5h before bed. Four weeks of beverages will be provided at a time. These beverage deposits will include an in person check in at the midpoint of the study. Participants and researchers will be blinded to the intervention groups. All participants will be given a 4-week supply of beverages. Investigators will meet with participants weekly via zoom/phone call and to report any adverse side effects or changes in physical activity routine. All products will be provided by Ocean Spray. All products are hemp derived, within legal limits and have had their purity verified. Following the completion of data collection for all study participants, researchers will be unblinded to supplementation groups.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Currently completing at least 150 minutes of moderate to vigorous physical activity per week - Have a body mass index under 29.9 - No significant physical or mental health (without the presence of chronic depression or anxiety) conditions - No presence or past diagnosis of eating disorders Exclusion Criteria: - Subjects may not have an allergy to soy. - All study subjects must also be free of cannabis product use or regular high doses of antioxidants for the previous 8 weeks. Participants receive a $200 Visa Gift Card after the last study visit is completed.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Daily Beverage Intervention
Individuals will consume one of 4 beverages, daily for 8 weeks.

Locations

Country Name City State
United States University Of Northern Colorado Greeley Colorado

Sponsors (1)

Lead Sponsor Collaborator
University of Northern Colorado

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Quality of Life Questionnaire Score Ferrans and Powers Quality of Life Index Questionnaire. A higher scores suggests higher quality of life. Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in Fatigue Score Piper Fatigue Questionnaire. A higher score suggests higher levels of fatigue. Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in Sleep Assessment Sleep Assessment (7 day). We will use Fitbits to track sleep. Just before the 8 Week Intervention and in the 7th Week of the 8 Week Intervention
Primary Change in Sleep Questionnaire Score Leeds Sleep Questionnaire. Lower scores generally suggest better sleep. Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in Physical Activity (steps per day) Physical Activity Assessment (7 day). We will use Fitbits to track physical activity. Just before the 8 Week Intervention and in the 7th Week of the 8 Week Intervention
Primary Change in Perceived Stress Scale Score Perceived Stress Questionnaire. A higher score suggests higher perceived stress. Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in General Anxiety Disorder Questionnaire Score General Anxiety Disorder Questionnaire 7. A higher score suggests higher levels of anxiety. Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in Psychological Wellbeing Scale Score Psychological Wellbeing Questionnaire. A higher score suggests better wellbeing. Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in Cognitive Function and Abilities Score Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Function Abilities - Short Form 8a. A higher score suggests higher cognitive ability. Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change In Cognitive Function Score PROMIS Cognitive Function - Short Form 8a. A higher score suggests higher cognitive ability. Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in Athlete Sickness and Illness Assessment Score The Wisconsin Upper Respiratory Symptom Survey. A higher scores suggests more respiratory symptoms. Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in Sustained Attention to Response Task (SART) Activity Sustained Attention to Response Task (SART) Activity Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in Maximal Anaerobic Power Wingate Power Test Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in Natural Killer (NK) Cell Number NK Cell Counts obtained on a flow cytometer. Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in Natural Killer (NK) Cell Function NK Cell Cellular Function Assay using Flow Cytometry Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in a Biomarker of Inflammation Serum C-Reactive Protein Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in a Biomarker of Neural Health Circulating Brain Derived Neurotropic Factor Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in a Stress Biomarker Serum Cortisol Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in Liver Health Biomarker I Serum Aspartate aminotransferase (AST) Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in Liver Health Biomarker II Serum Alanine aminotransferase (ALT) Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
Primary Change in Kidney Health Biomarker Serum creatinine Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1